RE:Analysis I agree, it’s crucial to acknowledge the concerns raised by investors regarding the delay publishing the Phase 2 data. The lack of transparency and communication on this matter has left shareholders, including myself feeling hesitant. While we can speculate on the reasons behind the delay, it would be more beneficial for management to provide a clear explanation to its investors. Transparent communication would help alleviate concerns and enable us to make informed decisions about our investments. While we acknowledge that regulations require time, it has been a two-year wait since the trial completion.
I suspect a trial coming up as mentioned in their latest MD&A at the bottom of page 9... The latest news release regarding the escalation trial and the 10,000 products available for May 2023 sounds promising.